CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...